NOVARTIS WINS APPROVAL FOR THE MOST EXPENSIVE GENE THERAPY TREATMENT

Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in …

NOVARTIS WINS APPROVAL FOR THE MOST EXPENSIVE GENE THERAPY TREATMENT Read More »